Skip to main content
Clinical Trials/JPRN-UMIN000032147
JPRN-UMIN000032147
Completed
Phase 1

A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade glioma - A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade glioma

Juntendo University Faculty of Medicine0 sites5 target enrollmentApril 9, 2018
Conditionsglioma

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
glioma
Sponsor
Juntendo University Faculty of Medicine
Enrollment
5
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 9, 2018
End Date
December 31, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Juntendo University Faculty of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia 2\)Have a history of a serious drug allergy 3\)Have a positive result of HIV or HTLV\-1 antibody test 4\)Have a serious cardiac disorder 5\)Have an active autoimmune disorder 6\)Have a cancer other than glioma 7\)Have an infectious disorder that is difficult to control 8\)Be a female who is pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials